Advertisement

Cellular and Humoral Studies of Malignant Melanoma

  • Ariel Hollinshead
  • Keith Tanner
  • W. Daniel Kundin

Abstract

Recent studies have provided additional information with regard to antigenic properties of melanoma cells. Some of these studies have been performed using material shed into culture media during the growth of melanoma cells. Reisfeld et al.(1980) describe melanoma-associated antigens (MAAs) shed in the culture media of radiolabeled melanoma cells, which react with polyclonal antimelanoma xenoantisera. MGP-1, a subunit of a larger structure, was described an antigen with a molecular weight of 240,000 that was exclusive to melanoma cells, and MGP-2, a single-chain antigen with a molecular weight of 94,000, was found to be present on melanoma cells, carcinoma cells, and fetal melanocytes. It was found that radiochemically pure antigens had different charge properties. In a recent review, these authors described the many variables to be considered in the evaluation of MAAs (Ferrone and Pellegrino, 1979). Gupta et al.(1979a) studied the antigenic activity of spent serum-free, chemically defined media by monitoring complement fixation and immune adherence. This group described two distinct antigens, namely, oncofetal antigen and tumor-associated antigen, (TAA). In a further study (Gupta and Morton, 1980), this group described the same TAA, derived from the M14 melanoma cell line after radiolabeling with 125I in radioimmunoassays (RIAs) with patient sera. Positive antibodies (positive antibody was defined as ≥ 1: 100 serum dilution) were in 65% of melanoma sera, 36% of carcinoma sera, and 15% of normal sera. Spent media of melanoma cell lines, or tumor extracts (63% of both), gave 50% inhibition, but little or no inhibition was seen using the spent media of sarcoma (0%), colon or breast cell lines (17%), or extracts of fetal and normal tissues (0%).

Keywords

Melanoma Cell Melanoma Patient Melanoma Cell Line Primary Melanoma Bacillus Calmette Guerin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arlen, M., Hollinshead, A. C., and Scherrer, J., 1977, Tumor-specific immunity in patients with malignant melanoma, Surg. Forum 27: 168–169.Google Scholar
  2. Carey, T. E., Lloyd, K. O., Takahashi, T., Travassos, L. R., and Old, L. J., 1979, AU cell-surface antigen in human malignant melanoma: Solubilization and partial characterization, Proc. Natl. Acad. Sci. U.S.A. 76(6): 2898–2902.PubMedCrossRefGoogle Scholar
  3. Carrel, S., Accolla, R. S., Carmagnola, A. L., and Mach, J.-P., 1980, Common human melanoma-associated antigen(s) detected by monoclonal antibodies, Cancer Res. 40: 2523–2528.PubMedGoogle Scholar
  4. Char, D. V., Hollinshead, A. C., Cogan, D. G., Ballantine, R. J., Hogan, M. J., and Herberman, R. B., 1974, Cutaneous delayed hypersensitivity reactions to soluble melanoma antigen in patients with ocular malignant melanoma, N. Engl. J. Med. 291: 274–277.PubMedCrossRefGoogle Scholar
  5. Char, D. V., Hollinshead, A. C., and Herberman, R. B., 1977, Skin tests with soluble melanoma antigens in patients with choroidal tumors, Cancer 40: 1650–1654.PubMedCrossRefGoogle Scholar
  6. Ferrone, S., and Pellegrino, M. A., 1979, Serological detection of human melanoma-associated antigens, in: Immunodiagnosis of Cancer, Vol. 9, Part I ( R. B. Herberman and R. W. McIntire, eds.), pp. 588–632, Marcel Dekker, New York.Google Scholar
  7. Gorodilova, V. A., and Hollinshead, A. C., 1975, Melanoma antigens that produce cell-mediated immune responses in melanoma patients: Joint US-USSR study, Science 190: 391–392.PubMedCrossRefGoogle Scholar
  8. Gorodilova, V. V., Hollinshead, A. C., and Babakova, S. V., 1976, Cell immunity reaction in patients with melanoma, Vopr. Oncol. 12: 1–5.Google Scholar
  9. Gupta, R. K., and Morton, D. L., 1980, Specificity by radioimmunoassay of tumor-associated antigen isolated from spent culture medium of a human melanoma cell line, Fed. Proc. Fed. Am. Soc. Exp. Biol. 39: 1144.Google Scholar
  10. Gupta, R. K., Irie, R. F., Chee, D. O., Kern, D. H., and Morton, D. L., 1979a, Demonstration of two distinct antigens in spent tissue culture medium of a human malignant melanoma cell line, J. Natl. Cancer Inst. 63(2): 347–356.Google Scholar
  11. Gupta, R. K., Silver, H. K., Reisfeld, R. A., and Morton, D. L., 1979b, Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography, Cancer Res. 39: 1683–1695.Google Scholar
  12. Helander, I., Nordman, E., Hakkinen, I. P., and Toivanen, A., 1979, Prolonged BCG treatment of melanoma: Does it suppress the immune capacity?, Br. J. Dermatol. 101(4): 421–427.PubMedCrossRefGoogle Scholar
  13. Hersey, P., Edwards, A., and McCarthy, W. H., 1980, Tumor-related changes in natural killer cell activity in melanoma patients: Influences of stage of disease, tumor thickness and age of patients, Int. J. Cancer 25(2): 187–194.PubMedCrossRefGoogle Scholar
  14. Hollinshead, A. C., 1975a, Delayed hypersensitivity reactions to soluble membrane antigens of human malignant melanoma cells in patients with systemic and ocular melanomas, Fed. Proc. Fed. Am. Soc. Exp. Biol. 34: 1042.Google Scholar
  15. Hollinshead, A. C., 1975b, Analysis of soluble melanoma cell membrane antigens in metastatic cells of various organs and further studies of antigens present in primary melanoma, Cancer 36: 1282–1288.CrossRefGoogle Scholar
  16. Hollinshead, A. C., 1978, Active-specific immunotherapy, in: Immunotherapy of Human Cancer, pp. 213–233, Raven Press, New York.Google Scholar
  17. Hollinshead, A. C., 1979a, Skin tests to identify TAA of melanoma for use in immunotherapy and to produce antisera to purified TAA for the development of radioimmunoassay, in: Compendium of Assays for Immunodiagnosis of Human Cancer( R. B. Herberman, ed.), pp. 605–610, Elsevier/North-Holland, New York.Google Scholar
  18. Hollinshead, A. C., 1979b, Melanoma tumor rejection antigen and its interrelationship with inhibitory or suppressor substances in vivoand in vitro, Symp. Abst. No. 6, Proc. VII Mtg. Intl. Oncodevelopmental Bio. and Med: Tumour Markers, Guilford, U. K.Google Scholar
  19. Hollinshead, A. C., and Chuang, C. Y., 1978, Evaluation of the relationships of prealbumin components in sera of patients with cancer, (Natl. Cancer Inst. Monogr. 49: 187–192.Google Scholar
  20. Hollinshead, A. C., Jaffurs, W., Alpert, L., and Herberman, R., 1973, Specific soluble membrane antigen of malignant and normal breast cells: Delayed hyper-sensitive skin reactions in cancer patients, Proc. II Intl. Sym. of Cancer Detection and Prevention, Bologna, Italy, pp. 647–654.Google Scholar
  21. Hollinshead, A. C., Herberman, R., Jaffurs, W., Alpert, L., Minton, J. P., and Harris, J. E., 1974, Soluble membrane antigens of human malignant melanoma cells, Cancer 34: 1235–1243.PubMedCrossRefGoogle Scholar
  22. Hollinshead, A. C., Chuang, C. Y., Cooper, E. H., and Catalona, W. J., 1977, Interrelationship of prealbumin and alpha,-acid glycoprotein in cancer patient sera, Cancer 40(6): 2993–2998.PubMedCrossRefGoogle Scholar
  23. Hollinshead, A. C., Stewart, T. H. M., Yonemoto, R., Arlen, M., and Takita, H., 1980, Immunotherapy of advanced disease, in: Tumor Progression( R. G. Crispin, ed.), pp. 289–300, Elsevier/North-Holland, New York.Google Scholar
  24. Hollinsheadé A. C., Arlen, M., Yonemoto, R., Cohen, M., Tanner, K., Kundin, W. D., and Scherrer, J., 1982, Pilot studies using melanoma tumor-associated antigen (TAA) in specific-active immunochemotherapy of malignant melanoma Cancer 49: in apress.Google Scholar
  25. Hughes, L. E., Kearney, R., and Tully, M., 1970, A study in clinical cancer immunotherapy, Cancer 26: 269–278.PubMedCrossRefGoogle Scholar
  26. Ishii, Y., and Mavligit, G., 1979, Soluble melanoma antigen: Its characterization and diagnostic detection by radioimmunoassay, in: Compendium of Assays for Immunodiagnosis of Human Cancer, Vol. 1 ( R. B. Herberman, ed.), pp. 591–596, Elsevier/North-Holland, New York.Google Scholar
  27. Jassem, J., Moszkowska, G., Mlodkowska, A., and Jaskiewicz, J., 1979, IgG, IgA and IgM levels and the presence of autoimmune antibodies against nuclei and smooth muscle in patients with malignant melanoma, Pol. Tyg. Lek. 34(21): 813–816.PubMedGoogle Scholar
  28. Kerney, S. E., Montague, P. M., Chretien, P. B., Nicholson, J. M., Ekel, T. M., and Hearing, V. J., 1977, Intracellular localization of tumor-associated antigens in murine and human malignant melanoma, Cancer Res. 37: 1519–1524.PubMedGoogle Scholar
  29. Klingler, W. G., Montague, P. M., Chretien, P. B., and Hearing, V. J., 1977, Atypical melanosomal proteins in human malignant melanoma, Arch. Dermatol. 113: 19–23.PubMedCrossRefGoogle Scholar
  30. Koprowski, H., Steplewski, Z., Herlyn, D., and Herlyn, M., 1978, Study of antibodies against human melanoma produced by somatic cell hybrids, Proc. Natl. Acad. Sci. U.S.A. 75(7): 3405–3409.PubMedCrossRefGoogle Scholar
  31. Kristensen, E., Langvad, E., and Reimann, R., 1976, Humoral immunity in malignant skin melanoma: Isolation of melanoma specific IgG from melanoma metastases, Eur. J. Cancer 12: 945–950.PubMedGoogle Scholar
  32. Lewis, M. G., and Phillips, T. M., 1972, The specificity of surface membrane immunofluorescence in human malignant melanoma, Int. J. Cancer 10: 105–111.PubMedCrossRefGoogle Scholar
  33. Lewis, M. G., Phillips, T. M., Noble, P. B., and Hartmann, D. P., 1979, Immune derangement in patients with malignant melanoma, J. Cutan. Pathol. 6(3): 201–207.PubMedCrossRefGoogle Scholar
  34. Liao, S. K., Rahman, A. F., Kwong, P. C., and Dent, P. B., 1979, A simple microassay for detection of antibodies to fetal calf serum and related antigens and its application to the serological definition of human tumor antigens, J. Immunol. Methods 27(2): 111–125.PubMedCrossRefGoogle Scholar
  35. Morgan, A. C., Halloway, D. M., Imai, K., Ferrone, S., and Reisfeld, R. A., 1980, The effects of inhibitors of glycosylation on the shedding and cell surface expression of human melanoma-associated antigens, Fed. Proc. Fed. Am. Soc. Exp. Biol. 39: 351.Google Scholar
  36. Morris, J. E., Egan, M. L., and Todd, C. W., 1975, The binding of carcinoembryonic antigen by antibody and its fragments, Cancer Res. 35: 1804–1808.PubMedGoogle Scholar
  37. Natali, P. G., Cordiali, P., Cavalieri, R., Di Filippo, F., Quaranta, V., Pellegrino, M. A., and Ferrone, S., 1980, Reactivity of HLA-DR monoclonal antibodies with freshly explanted melanoma cells, but not with nevi cells, Fed. Proc. Fed. Am. Soc. Exp. Biol. 39: 684.Google Scholar
  38. Ninger, E., Zemanova, D., Kovarik, J., and Lauerova, L., 1979, Evaluation of three E-rosette assays in melanoma patients, Cancer Immunol. Immunother. 6(2): 121–124.CrossRefGoogle Scholar
  39. Otterstrom, J. R., 1979, Research on the nature of tumor rejection antigens of an ultroviolet light induced murine skin tumor, Diss. Abstr. Int. B 40(4): 1695B.Google Scholar
  40. Reisfeld, R. A., Galloway, D., Imai, K., Ferrone, S., and Morgan, A. C., 1980, Molecular profiles of human melanoma associated antigens, Fed. Proc. Fed. Am. Soc. Exp. Biol. 39: 351.Google Scholar
  41. Saxton, R. E., Burk, M., Meier, S., and Morton, D. L., 1980, Hybridoma monoclonal antibody: Use in defining unique antigens on human melanoma cells, Fed. Proc. Fed. Am. Soc. Exp. Biol. 39: 1144.Google Scholar
  42. Stein, J. A., Adler, A., Czernobilsky, B., Goldfarb, A. J., Rozin, R. R., Teva, Z., and Stavorovsky, M., 1979, Cutaneous response to autochthonous tumor cells in breast cancer and melanoma patients by active immunization, Proceedings of the Serono Symposia, Vol. 16, Tumor-Associated Antigens and Their Specific Immune Response, pp. 343–353.Google Scholar
  43. Stuhlmiller, G., and Seigler, H. F., 1979, Melanoma cell membrane tumor-associated antigens in: Compendium of Assays for Immunodiagnosis of Human Cancer, Vol. 1 (R. B. Herberman, ed.), pp. 591–596, Elsevier/ North-Holland, New York.Google Scholar
  44. Thatcher, N., Swindell, R., and Crowther, D., 1979, Effects of repeated Corynebacterium paroumand BCG therapy on immune parameters: A weekly study of melanoma patients. II. Changes in serum immunoglobulins and lymphoid cell subpopulations, Clin. Exp. Immunol. 36(3): 456–464.PubMedGoogle Scholar
  45. Vandenbark, A. A., Greene, M. H., Burger, D. R., Vetto, R. M., and Reimer, R. R., 1979, Immune response to melanoma extracts in three melanoma-prone families, J. Natl. Cancer Inst. 63(5): 1147–1151.PubMedGoogle Scholar
  46. Van Der Giessen, M., The, T. H., Schraffordt Kiips, H., Van Wingerden, I., and Rumke, P. H., 1978, Detection, isolation and characterization of immune complexes in malignant melanoma, Protides Biol. Fluids Proc. Collog. 26: 341–344.Google Scholar
  47. Van Wingerden, I., The, T. H., Van Der Giessen, M. and Rumke, P. H., 1978, Demonstration of circulating immune complexes in melanoma patients by means of a granulocyte phagocytosis test, Protides Biol. Fluids Proc. Colloq. 26: 345–348.Google Scholar
  48. West, W. H., 1979, E-rosette formation in immunodiagosis, in: Immunodiagnosis of Cancer, Vol. 9, Part 2 ( R. B. Herberman and R. W. McIntire, eds.), pp. 704–721, Marcel Dekker, New York.Google Scholar
  49. Winkelhake, J. L., Elcombe, B. M., and Hodach, A., 1979, Immunological block to synthetic alpha-melanocytestimulating hormone-melanocyte interaction by antibodies isolated from cell column immunoadsorbents, Cancer Res. 39(8): 3058–3064.PubMedGoogle Scholar
  50. Yeh, M. Y., Hellström, I., Brown, J. P., Warner, H. A., Hansen, J. A., and Hellström, K. E., 1979, Cell surface antigens of human melanoma identified by monoclonal antibody, Proc. Natl. Acad. Sci. U.S.A. 76(6): 2927–2931.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Ariel Hollinshead
    • 1
  • Keith Tanner
    • 1
  • W. Daniel Kundin
    • 1
  1. 1.Division of Hematology and Oncology, Department of MedicineThe George Washington University Medical CenterUSA

Personalised recommendations